Best Seller Of Delamanid CAS NO (681492-22-8) Available at good Price

Delamanid (681492-22-8)

1. Chemical Identity: Delamanid, with the CAS number 681492-22-8, is a chemical compound belonging to the class of nitro-dihydro-imidazooxazoles. It possesses a unique molecular structure characterized by its nitroimidazole core, which underpins its pharmacological activity.

2. Discovery and Development: Delamanid was developed by Otsuka Pharmaceutical Co., Ltd. as a novel antituberculosis agent. It underwent extensive preclinical and clinical evaluations to assess its efficacy, safety, and pharmacokinetic properties, culminating in its approval for the treatment of multidrug-resistant tuberculosis (MDR-TB).

3. Mechanism of Action: Delamanid exerts its antimycobacterial activity by inhibiting the synthesis of mycolic acids, crucial components of the mycobacterial cell wall. Specifically, it targets the enzyme DprE1, disrupting the synthesis of decaprenylphosphoryl-β-D-ribose 2′-epimerase, which is essential for cell wall biosynthesis in Mycobacterium tuberculosis.

4. Therapeutic Applications: Delamanid is indicated for the treatment of pulmonary MDR-TB in combination with other antituberculosis medications. It offers an important therapeutic option for patients with drug-resistant tuberculosis, particularly in settings where alternative treatment options are limited or ineffective.

5. Treatment Regimens: Delamanid is typically administered orally as part of a multidrug regimen for the treatment of MDR-TB. The recommended dosage and duration of treatment may vary depending on factors such as the severity of the disease, treatment history, and individual patient characteristics.

6. Clinical Efficacy: Clinical trials have demonstrated the efficacy of delamanid in reducing sputum culture conversion time and improving treatment outcomes in patients with MDR-TB. It has shown favorable results in terms of bactericidal activity and reducing the risk of disease recurrence compared to standard treatment regimens.

7. Safety Profile: Delamanid is generally well-tolerated, with most adverse effects being mild to moderate in severity. Common side effects include gastrointestinal symptoms such as nausea, vomiting, and abdominal pain, as well as elevated liver enzymes. Close monitoring of liver function and adverse reactions is recommended during treatment.

8. Pediatric Use: Delamanid has also been studied and approved for use in pediatric patients with MDR-TB, providing a valuable treatment option for children and adolescents affected by drug-resistant tuberculosis. Dosing regimens and safety considerations may differ from those in adults and require careful evaluation.

9. Global Access and Challenges: Despite its efficacy, access to delamanid remains limited in many regions with high burdens of drug-resistant tuberculosis due to factors such as cost, regulatory hurdles, and healthcare infrastructure challenges. Efforts to improve global access to this important medication are ongoing.

10. Future Directions: Continued research and development efforts aim to optimize delamanid's therapeutic utility, expand its indications, and address challenges related to drug resistance, treatment adherence, and pharmacovigilance. Collaboration between governments, healthcare organizations, and pharmaceutical companies is crucial to maximize the impact of delamanid in combating drug-resistant tuberculosis on a global scale.